{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:13:56Z","timestamp":1780755236793,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.farma.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T11:12:11Z","timestamp":1722078731000},"page":"T272-T277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020"],"prefix":"10.1016","volume":"48","author":[{"given":"Hilario","family":"Mart\u00ednez-Barros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Pousada-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pedreira-Bouzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Clop\u00e9s-Estela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.farma.2024.07.006_bb0005","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","article-title":"Precision oncology: origins, optimism, and potential","volume":"17","author":"Prasad","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.farma.2024.07.006_bb0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.farma.2024.07.006_bb0015","doi-asserted-by":"crossref","unstructured":"Nieto-G\u00f3mez P., Casta\u00f1o-Amores C., Rodr\u00edguez-Delgado A. and \u00c1lvarez-S\u00e1nchez R., Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement, Eur J Health Econ., 25 (2), 2024, 257-267, doi:10.1007\/s10198-023-01584-9.","DOI":"10.1007\/s10198-023-01584-9"},{"issue":"12","key":"10.1016\/j.farma.2024.07.006_bb0020","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer."},{"issue":"12","key":"10.1016\/j.farma.2024.07.006_bb0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2022.4924","article-title":"Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration From 2015 to 2020","volume":"182","author":"Iljkovic","year":"2022","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.farma.2024.07.006_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2021.12.037","article-title":"Characteristics of clinical trials for haematological malignancies from 2015 to 2020: a systematic review","volume":"167","author":"Wesson","year":"2022","journal-title":"Eur J Cancer."},{"issue":"5","key":"10.1016\/j.farma.2024.07.006_bb0035","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomised clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.farma.2024.07.006_bb0040","series-title":"Informe evoluci\u00f3n de la financiaci\u00f3n y fijaci\u00f3n de precio de los medicamentos oncol\u00f3gicos en el SNS (2016\u20132021) [Internet]","author":"Direcci\u00f3n General de Cartera Com\u00fan de Servicios del SNS y Farmacia","year":"2022"},{"issue":"6","key":"10.1016\/j.farma.2024.07.006_bb0045","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1470-2045(23)00175-4","article-title":"Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study","volume":"24","author":"Jenei","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.farma.2024.07.006_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1130-6343(07)75703-3","article-title":"Acceso a nuevos f\u00e1rmacos oncol\u00f3gicos en Europa: el debate generado por el \u201cInforme Karolinska\u201d","volume":"31","author":"Clop\u00e9s Estela","year":"2007","journal-title":"Farm Hosp."},{"key":"10.1016\/j.farma.2024.07.006_bb0055","series-title":"EFPIA Patients W.A.I.T. Indicator 2021 Survey [Internet]","author":"Newton","year":"2022"},{"key":"10.1016\/j.farma.2024.07.006_bb0060","series-title":"ESMO-Magnitude of Clinical Benefit Scale [Internet]","author":"European Society of Medical Oncology","year":"2023"},{"key":"10.1016\/j.farma.2024.07.006_bb0065","series-title":"Bavencio assessment report EMEA\/H\/C\/004338\/0000 [Internet]","author":"European Public Assessment Report","year":"2017"},{"key":"10.1016\/j.farma.2024.07.006_bb0070","series-title":"Tecentriq assessment report EMEA\/H\/C\/004143\/0000 [Internet]","author":"European Public Assessment Report","year":"2017"},{"issue":"359","key":"10.1016\/j.farma.2024.07.006_bb0075","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009\u201313","volume":"4","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.farma.2024.07.006_bb0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10637-022-01227-5","article-title":"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA","volume":"40","author":"Michaeli","year":"2022","journal-title":"Invest New Drugs."},{"issue":"5","key":"10.1016\/j.farma.2024.07.006_bb0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamaoncol.2021.8206","article-title":"Biased evaluation in cancer drug trials-how use of progression-free survival as the primary end point can mislead","volume":"8","author":"Tannock","year":"2022","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.farma.2024.07.006_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med."},{"issue":"12","key":"10.1016\/j.farma.2024.07.006_bb0095","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/S1470-2045(16)30572-1","article-title":"Relevance of randomised controlled trials in oncology","volume":"17","author":"Tannock","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.farma.2024.07.006_bb0100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomised trials in cochrane reviews: the ROBES meta-epidemiologic study","volume":"187","author":"Savovic","year":"2018","journal-title":"Am J Epidemiol."},{"issue":"3","key":"10.1016\/j.farma.2024.07.006_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100117","article-title":"Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring","volume":"6","author":"Gyawali","year":"2021","journal-title":"ESMO Open."},{"issue":"7","key":"10.1016\/j.farma.2024.07.006_bb0110","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3026(23)00130-8","article-title":"The essential role of randomised controlled trials","volume":"10","author":"Marini","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.farma.2024.07.006_bb0115","series-title":"Recomendaciones sobre la gesti\u00f3n de medicamentos autorizados por la Comisi\u00f3n Europea por procedimiento centralizado, sin resoluci\u00f3n definitiva de precio y financiaci\u00f3n en Espa\u00f1a, tengan o no otra indicaci\u00f3n ya con decisi\u00f3n de precio [internet]","author":"Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del SNS","year":"2023"},{"key":"10.1016\/j.farma.2024.07.006_bb0120","series-title":"Propuesta de reforma del Procedimiento de evaluaci\u00f3n de medicamentos en Espa\u00f1a [internet]","author":"Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del SNS","year":"2023"},{"issue":"5","key":"10.1016\/j.farma.2024.07.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1229","article-title":"Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries","volume":"3","author":"Chow","year":"2022","journal-title":"JAMA Health Forum."},{"issue":"5","key":"10.1016\/j.farma.2024.07.006_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","article-title":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland","volume":"20","author":"Michaeli","year":"2022","journal-title":"Appl Health Econ Health Policy."},{"issue":"6","key":"10.1016\/j.farma.2024.07.006_bb0135","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomised clinical trials leading to anticancer drug approval by the US Food and Drug Administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.farma.2024.07.006_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cct.2013.12.003","article-title":"The misguided ethics of crossover trials","volume":"37","author":"Prasad","year":"2014","journal-title":"Contemp Clin Trials."},{"issue":"18","key":"10.1016\/j.farma.2024.07.006_bb0145","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1158\/1078-0432.CCR-11-3118","article-title":"Overestimation of the effect size in group sequential trials","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"33","key":"10.1016\/j.farma.2024.07.006_bb0150","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T05:50:17Z","timestamp":1731649817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1130634324001211"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.07.006","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}